Enter a phrase above to search files and articles within the site.

Typically materials that are more than 5 years old will be archived

Raynaud’s Phenomenon

https://www.niams.nih.gov/health-topics/raynauds-phenomenon

What is Raynaud’s phenomenon? Raynaud’s phenomenon is a condition that affects your blood vessels. If you have Raynaud’s phenomenon, you have periods of time called “attacks” when your body does not send enough blood to the hands and feet. Attacks usually happen when you are cold or feeling stressed. During an attack, your fingers and toes may feel very cold or numb. Raynaud’s phenomenon is also called Raynaud’s disease or Raynaud’s syndrome.

The Effect of Atorvastatin on Microvascular Endothelial Function and Raynaud in Early Diffuse Systemic Sclerosis

https://www.niams.nih.gov/grants-funding/clinical-trials-spotlight/effect-atorvastatin-microvascular-endothelial-function-and

The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) supports a range of clinical trials studying new and existing interventions for prevention and treatment of arthritis, musculoskeletal, and skin diseases. Recruitment for this clinical trial complete. Updates will be made to this page when the study completes data

What Is NIAMS?

https://www.niams.nih.gov/about/what-is-niams

The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) is one of 27 Institutes and Centers at the National Institutes of Health (NIH), the nation’s premier biomedical research agency. Established in 1986, the NIAMS supports research into the causes, treatment, and prevention of arthritis and musculoskeletal and skin diseases; the training of basic and clinical scientists to carry out this research; and the dissemination of information on research progress in these diseases.

Honoring Health — What Your Community Needs To Know About COVID-19 — April 2020

https://www.niams.nih.gov/newsletters/aian-newsletter/2020/aian-newsletter-april-2020

p.no-pdf a.pdf:before { content: ''; } @media only screen and (min-width: 601px) { img.align-right { width: 22% !important; } } .photo.right { display: none; } hr { clear: both; border-right: medium none; border-top: 1px solid rgba(0,0,0,.1); border-left: medium none; border-bottom: medium none; height: 1px; } What Your Community Needs To Know About COVID-19 The coronavirus disease 2019 (COVID-19) pandemic is an emerging, rapidly evolving situation. For this reason, we are focusing this issue of Honoring Health on the latest public health and research information available, to help you keep your community informed. Featured Health Information Latest Public Health Information From

What Others are Saying About the Accelerating Medicines Partnership’s Rheumatoid Arthritis and Lupus Network Awards

https://www.niams.nih.gov/grants-funding/funded-research/accelerating-medicines/what-others-are-saying

NIAMS updated this page February 13, 2017, due to organization name changes. What Others are Saying About the Accelerating Medicines Partnership’s Rheumatoid Arthritis and Lupus Network Awards AbbVie: "AbbVie is proud to support the AMP RA/Lupus Network and collaborate on emerging research to improve the treatment options for patients living

Systemic Lupus Erythematosus (Lupus)

https://www.niams.nih.gov/health-topics/lupus

What is systemic lupus erythematosus (lupus)? Systemic lupus erythematosus (lupus) is a chronic (long-lasting) autoimmune disease that can affect many parts of the body, including the: Skin. Joints. Heart. Lungs. Kidneys. Brain. Lupus happens when the immune system, which normally helps protect the body from infection and disease, attacks its own tissues. This attack causes inflammation and, in some cases, permanent tissue damage. If you have lupus, you may have times of illness (flares) and times of wellness (remission). Lupus flares can be mild to serious, and they do not follow a pattern. However, with treatment, many people with lupus

Roundtable on Scleroderma: Advancing Potential Drugs to Patient Care

https://www.niams.nih.gov/about/meetings-events/roundtables/roundtable-scleroderma-advancing-potential-drugs-patient-care

Roundtable on Scleroderma: Advancing Potential Drugs to Patient Care February 27, 2015 Background Scleroderma is a complex disease resulting from inflammation and soft tissue fibrosis (hardening). The organ and tissue systems affected by the disease include skin, blood vessels, gastrointestinal tract, lung, heart, kidney, muscles, and joints. Scleroderma is considered an autoimmune disease, in which much of the tissue damage is thought to be caused by the patient’s own immune system. Clinically, this progressive disease is challenging to treat or prevent since there is no proven, approved therapy to alter the underlying cause. Fibrosis results in high morbidity for patients

Roundtable on Scleroderma: Advancing Potential Drugs to Patient Care

https://www.niams.nih.gov/newsroom/meetings-events/roundtables/scleroderma-advancing-potential-drugs-to-patient-care

Background Scleroderma is a complex disease resulting from inflammation and soft tissue fibrosis (hardening). The organ and tissue systems affected by the disease include skin, blood vessels, gastrointestinal tract, lung, heart, kidney, muscles, and joints. Scleroderma is considered an autoimmune disease, in which much of the tissue damage is thought to be caused by the patient’s own immune system. Clinically, this progressive disease is challenging to treat or prevent since there is no proven, approved therapy to alter the underlying cause. Fibrosis results in high morbidity for patients with substantial impact on their quality of life, as well as high

Clinical Trials in the Spotlight - Completed Recruitment

https://www.niams.nih.gov/grants-funding/clinical-trials-spotlight/clinical-trials-spotlight-completed-recruitment

Studies That Have Completed Recruitment Trials that are no longer recruiting but remain active to complete other study activities are found here. Click on a disease/condition below to learn more about a range of clinical trials studying new and existing interventions for prevention and treatment of arthritis, musculoskeletal and skin

Roundtable on the Role of Disc Degeneration in Neck and Back Pain

https://www.niams.nih.gov/about/meetings-events/roundtables/roundtable-role-disc-degeneration-neck-and-back-pain

Meeting Summary Also see Role of Disc Degeneration in Pain Explored, NIH Record (January 16, 2015) Scroll down to fifth item. Background Neck and back pain is a significant public health problem in the United States. Approximately 11-14 percent of working age adults will experience work-related activity limitations due to neck pain.1 Many more are affected by low back pain; 70 percent of Americans experience low back pain that is serious enough to disrupt daily routines during their lifetime.2 Chronic spinal pain is often progressive, and its causes can be difficult to determine. It also is expensive. Low back pain

Tendinopathy Education on the Achilles, A Clinical Trial (TEACH)

https://www.niams.nih.gov/grants-funding/clinical-trials-spotlight/tendinopathy-education-achilles-clinical-trial-teach

Clinical Trials in the Spotlight Main Page The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) supports a range of clinical trials studying new and existing interventions for prevention and treatment of arthritis, musculoskeletal, and skin diseases. Investigators supported by the NIAMS need your help finding individuals to

June 5, 2019 Council Minutes

https://www.niams.nih.gov/about/working-groups/advisory-council/council-minutes/june-5-2019-council-minutes

DEPARTMENT OF HEALTH AND HUMAN SERVICES PUBLIC HEALTH SERVICE NATIONAL ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES ADVISORY COUNCIL MINUTES OF THE 98th MEETING June 5, 2019 8:30 a.m. to 3:00 p.m. June 5th, 2019 Webcast I. CALL TO ORDER The 98th meeting of the National Arthritis and Musculoskeletal and Skin Diseases Advisory Council (NAMSAC) was held on June 5, 2019, at the National Institutes of Health (NIH) Campus, Building 45, Conference Rooms E1/E2. The meeting was chaired by Dr. Robert H. Carter, Acting Director, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). Attendance Council members present: Ms. Karen

February 4, 2015 Council Minutes

https://www.niams.nih.gov/about/working-groups/advisory-council/council-minutes/february-4-2015-council-minutes

Department of Health and Human Services Public Health Service National Arthritis and Musculoskeletal and Skin Diseases Advisory Council Minutes of the 85th Meeting 8:30 a.m. to 3:00 p.m. CALL TO ORDER The 85th meeting of the National Arthritis and Musculoskeletal and Skin Diseases Advisory Council (NAMSAC) was held on February 4, 2015, at the National Institutes of Health (NIH) Campus, Building 31, Conference Room 6. The meeting was chaired by Dr. Stephen I. Katz, Director, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). Attendance Council members present Dr. Joan E. Bechtold Dr. Sherine E. Gabriel Ms. Michelle Hofhine

February 5, 2013 Council Meeting Minutes

https://www.niams.nih.gov/about/working-groups/advisory-council/council-minutes/february-5-2013-council-meeting-minutes

Department of Health and Human Services Public Health Service National Arthritis and Musculoskeletal and Skin Diseases Advisory Council Minutes of the 79th Meeting 8:30 a.m. to 2:15 p.m. CALL TO ORDER The 79th meeting of the National Arthritis and Musculoskeletal and Skin Diseases Advisory Council (NAMSAC) was held on February 5, 2013, at the National Institutes of Health (NIH) Campus, Building 31, Conference Room 6. The meeting was chaired by Dr. Stephen I. Katz, Director, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). Attendance Council members present Dr. Lynda F. Bonewald Dr. David R. Eyre Dr. Gary Firestein

Strategic Plan Fiscal Years 2020-2024

https://www.niams.nih.gov/about-niams/strategic-plan-fiscal-years-2020-2024

PDF Version – Strategic Plan Fiscal Years 2020–2024 (1171 KB) Table of Contents DIRECTOR’S MESSAGE EXECUTIVE SUMMARY INTRODUCTION, MISSION, AND STRUCTURE Introduction Mission and Statutory Authority NIAMS Organizational Structure CROSS-CUTTING SCIENTIFIC THEMES Precision Medicine for Arthritis and Musculoskeletal and Skin Diseases Shared Mechanisms in Health and Among Diseases Patient-Centric Approaches